This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Policy

InOncology.com

ELCC 2018

European Lung Cancer Congress 2018

This event has ended

At the 2018 European Lung Cancer Congress (ELCC), Boehringer Ingelheim hosted a satellite symposium entitled ‘Points of view: opportunities and remaining hurdles in thoracic malignancies’. The event was chaired by Professor Dean A. Fennell and included presentations from Professor Martin Schuler and Professor Nicolas Girard.

Please see below for the downloadable versions of the presentations from this symposium, as well as details of other BI activities at ELCC 2018.

ELCC Symposium Webcast

 

1. EGFR TKI sequencing: does order matter? | Nicolas Girard

Rate this
Rate this
Rate this

2. Improving outcomes for NSCLC patients with brain metastases | Martin Schuler

Rate this
Rate this

3. Treatment of unresectable malignant pleural mesothelioma: current armamentarium and future prospects | Dean Fennell

Rate this
Rate this

ELCC symposium presentations

1. EGFR TKI sequencing: does order matter? | Nicolas Girard

2. Improving outcomes for NSCLC patients with brain metastases | Martin Schuler

3. Treatment of unresectable malignant pleural mesothelioma: current armamentarium and future prospects | Dean Fennell

Download a copy of the agenda below

Didn’t make it to ELCC 2018? Find out more about other oncology events

Click here to find out more about other oncology meetings, congresses, symposia and activities sponsored by Boehringer Ingelheim.

* Afatinib is approved in more than 70 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.

**Nintedanib is being investigated in malignant pleural mesothelioma (MPM) and is not approved for this use. The efficacy and safety of nintedanib in MPM have not been established.

© 2018 Boehringer Ingelheim International GmbH. All rights reserved.

Last updated: February 2018